High Serum Lactate Dehydrogenase adds Prognostic Value to Cardiac Biomarker Staging System for Light Chain Amyloidosis

Abstract In a patient with known sickle cell beta 0-thalassemia we measured serum lactate dehydrogenase (LD) activity and 24-h urinary creatine excretion rate as markers to evaluate sickle cell crises. We believe that a distinction based on biochemical findings can be made between hemolytic and painful vaso-occlusive sickle cell crises with muscular involvement. To assess hemolytic crises by objective biochemical measures, we have used assay of LD activity, and to assess painful crises with muscular involvement objectively, the 24-h urinary creatine excretion rate. We conclude that hemolytic crises are characterized by high serum LD activities. Furthermore, we conclude that--at least in this patient--painful crises are accompanied by high 24-h urinary creatine excretion rates. Our findings suggest that muscle involvement may play an important role in painful vaso-occlusive sickle cell crises.

Download Full-text

Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

PLoS ONE ◽

10.1371/journal.pone.0166482 ◽

2016 ◽

Vol 11 (11) ◽

pp. e0166482 ◽

Cited By ~ 12

Author(s):

Jie Shen ◽

Zhen Chen ◽

Qianfeng Zhuang ◽

Min Fan ◽

Tao Ding ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Lactate Dehydrogenase ◽

Cell Carcinoma ◽

Renal Cell ◽

Prognostic Value ◽

Meta Analysis ◽

Serum Lactate ◽

Serum Lactate Dehydrogenase

Download Full-text

Intratumoral lactate dehydrogenase 5 (LDH5) protein expression is associated with expression of angiogenesis markers and hypoxia in patients with colorectal cancer (CRC)

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.4107 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 4107-4107

Author(s):

M. I. Koukourakis ◽

A. Giatromanolaki ◽

E. Sivridis ◽

K. C. Gatter ◽

A. L. Harris ◽

...

Keyword(s):

Lactate Dehydrogenase ◽

Protein Expression ◽

Kinase Inhibitor ◽

Tumor Hypoxia ◽

Surrogate Marker ◽

Metastatic Tumor ◽

Therapeutic Benefit ◽

Serum Lactate ◽

High Serum ◽

Serum Lactate Dehydrogenase

4107 Background: Recent clinical trials (CONFIRM 1 and CONFIRM 2) have shown that metastatic CRC patients (pts) with high serum lactate dehydrogenase (LDH) derive the greatest therapeutic benefit from PTK787/ZK 222584 (PTK/ZK). PTK/ZK is a novel, oral tyrosine kinase inhibitor (TKI), which blocks all known VEGF receptors (VEGFR). From previous studies, total LDH and isoenzyme LDH5 have been associated with tumor aggressiveness and hypoxia. In the present study, we tested whether CRC pts with high levels of tumor LDH5 have increased expression of proteins involved with hypoxia (hypoxia inducible factors [HIF1a and 2a], pyruvate dehydrokinase [PDHK]), increased vessel density (VD), angiogenesis (VEGFA; phosphorylated VEGFR2 [pKDR]), acidity (carbonic anhydrase 9 [CA9]), and others. Methods: Baseline sections from either primary or metastatic tumor sites from 42 pts of the CONFIRM 1 and 2 trials were analysed with immunohistochemistry utilizing an established nominal scoring system. The degree of association between the scores of protein expressed was estimated by the phi-coefficient (correlation coefficient) and assessed by means of p-values from pairwise Fisher’s exact test (two- sided). Results: Associations were observed between LDH5 and the following: pKDR (Phi=.53; p<.001), VEGF (Phi=.41; p=.006), HIF-1a (Phi=.56; p<.001), VD (Phi=.34; p=.052), and PDHK (Phi=.58; p=.014), respectively. HIF-1a associated with pKDR (Phi=.38; p=.027), VD (Phi=.34; p=.045), and VEGFA (Phi=.33; p=.067). VEGFA associated with PDHK (Phi=.52; p=.035). Conclusions: Our results demonstrate that mCRC patients with high level of intratumoral protein expression of LDH5 have elevated HIF-1a, pKDR, VEGFA, PDHK expression and VD. These results support the concept that tumor hypoxia and angiogenesis are associated and that elevated LDH protein expression may serve as a surrogate marker for activated HIF-1a pathway. No significant financial relationships to disclose.

Download Full-text

99: Prognostic Value of Pre-Treatment Serum Lactate Dehydrogenase in HPV-Related and HPV-Unrelated Oropharyngeal Cancer

Radiotherapy and Oncology ◽

10.1016/s0167-8140(16)33498-3 ◽

2016 ◽

Vol 120 ◽

pp. S38-S39

Author(s):

Shao Hui Sophie Huang ◽

Scott V. Bratman ◽

Jie Su ◽

Li Tong ◽

John Kim ◽

...

Keyword(s):

Lactate Dehydrogenase ◽

Oropharyngeal Cancer ◽

Prognostic Value ◽

Serum Lactate ◽

Serum Lactate Dehydrogenase ◽

Pre Treatment

Download Full-text

High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma

Annals of Internal Medicine ◽

10.7326/0003-4819-115-12-931 ◽

1991 ◽

Vol 115 (12) ◽

pp. 931 ◽

Cited By ~ 116

Author(s):

Meletios A. Dimopoulos

Keyword(s):

Multiple Myeloma ◽

Drug Resistance ◽

Lactate Dehydrogenase ◽

Lactate Dehydrogenase Level ◽

Serum Lactate ◽

High Serum ◽

Serum Lactate Dehydrogenase ◽

Short Survival ◽

Serum Lactate Dehydrogenase Level

Download Full-text

Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms

Oncotarget ◽

10.18632/oncotarget.9459 ◽

2016 ◽

Vol 7 (26) ◽

pp. 39945-39956 ◽

Cited By ~ 5

Author(s):

Zi-Xian Wang ◽

Lu-Ping Yang ◽

Miao-Zhen Qiu ◽

Zhi-Qiang Wang ◽

Yi-Xin Zhou ◽

...

Keyword(s):

Gastric Cancer ◽

Lactate Dehydrogenase ◽

Prognostic Value ◽

Serum Lactate ◽

Serum Lactate Dehydrogenase ◽

Preoperative Serum ◽

Resectable Gastric Cancer

Download Full-text

Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.8093 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 8093-8093 ◽

Cited By ~ 1

Author(s):

Krina K. Patel ◽

Robert Z. Orlowski ◽

Donna M. Weber ◽

Michael Wang ◽

Sheeba K. Thomas ◽

...

Keyword(s):

Multiple Myeloma ◽

Lactate Dehydrogenase ◽

Prognostic Value ◽

Intensive Therapy ◽

Serum Lactate ◽

Response To Therapy ◽

Stage Iii ◽

Serum Lactate Dehydrogenase ◽

Survival Times ◽

The Impact

8093 Background: In patients with symptomatic multiple myeloma, the clinical features, responses to treatment, and survival times vary. Well established predictors of survival include the International Staging System (ISS), cytogenetic abnormalities, and response to therapy. Long recognized has been the association of high serum lactate dehydrogenase (LDH) with advanced disease and shorter survival. We focused here on the impact of high LDH on staging and prognosis in order to guide the role of recent advances in therapy. Methods: We evaluated 1,247 patients with newly diagnosed, symptomatic myeloma from 10/74 to 7/11. Our goal was to determine the prognostic value of high LDH (>300 IU/L) in relation to ISS stage. We also compared the frequencies of anemia, hypercalcemia, and response to therapy in patients with high LDH with those of patients with Stage III disease and normal LDH values. Results: All 1,139 patients with normal LDH lived significantly longer than the 108 patients with elevated values (47 vs. 16 months, p <.01). LDH was elevated in 9% of all patients, but in 2%, 6%, and 18% of patients with ISS-I, II, and III disease, respectively. Their survival times were also significantly shorter than those of comparable patients in each stage with normal LDH (table). Among the 108 patients with high LDH, the frequencies of hemoglobin <8.5 g/dl (54 vs. 41%, p=.03), and serum calcium>11.5 mg/dl (41 vs. 27%, p<.01) were significantly higher than those of 292 patients with Stage III disease and normal LDH, and the frequency of response to therapy was less (40 vs. 62%, p<.01). Conclusions: Serum lactate dehydrogenase provides a convenient and dependable prognostic indicator in patients with multiple myeloma. An elevated LDH value indicates a poor prognosis regardless of ISS stage, confirming the report by Gkotzamanidou, Terpos, and Dimopoulos et al, and should be included in the definition of stage III disease. Such patients require rapid control of disease with sequential combinations of effective drugs and intensive therapy in order to improve their outcome. [Table: see text]

Download Full-text